Articles with "patients pdac" as a keyword



Photo from wikipedia

NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype

Sign Up to like & get
recommendations!
Published in 2020 at "Oncoimmunology"

DOI: 10.1080/2162402x.2020.1845424

Abstract: ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is one of the most common tumor subtypes and remains associated with very poor survival. T cell infiltration into tumor tissue is associated with improved clinical outcome but little is… read more here.

Keywords: phenotype; tumor tissue; tumor; cells pancreatic ... See more keywords

Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis

Sign Up to like & get
recommendations!
Published in 2019 at "BMC Cancer"

DOI: 10.1186/s12885-019-5744-8

Abstract: BackgroundWith the increase in cancer survivors, more pancreatic ductal adenocarcinomas (PDACs) are developing as second primary cancers. Whether a prior cancer has an inferior impact on survival outcomes in patients with PDAC remains unknown, and… read more here.

Keywords: outcomes patients; survival outcomes; analysis; patients pdac ... See more keywords
Photo from wikipedia

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma

Sign Up to like & get
recommendations!
Published in 2022 at "Cancers"

DOI: 10.3390/cancers14246223

Abstract: Simple Summary Metastatic pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that has limited treatment options. Standard of care treatment involves systemic chemotherapy, although all tumors invariably develop resistance to these cytotoxic therapies. With the… read more here.

Keywords: metastatic pancreatic; targeted therapies; patients pdac; adenocarcinoma ... See more keywords
Photo from wikipedia

Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma

Sign Up to like & get
recommendations!
Published in 2023 at "Cancers"

DOI: 10.3390/cancers15030897

Abstract: Simple Summary During the last decades, the CA 19-9 blood test has been the only widely used biomarker in patients with pancreatic ductal adenocarcinoma (PDAC). Given the poor prognosis and staggering mortality rates of this… read more here.

Keywords: ductal adenocarcinoma; value; patients pdac; pancreatic ductal ... See more keywords